Company insider dossier

Bio-Rad Laboratories Inc insider intelligence

BIO-B filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Medical Devices Data API
20/100

Concentrated distribution

60/100 confidence
Exchange
NYSE
Sector
Healthcare
Industry
Medical Devices
Latest evidence
25 Jul 2026

Investment committee read

Concentrated distribution

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Review exposure and filing context

Evidence in favour

  • Participation spans 7 named insiders rather than one filing source.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
  • Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
Conviction20Concentrated distribution
Confidence60Developing
Named insiders7participating in the tape
Controlled events4directional common-share events
Acquisition value$0normalized amount
Disposal value$306.6Knormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

337.00309.07281.14253.22225.29 Acquisition · 25 Jul 2026 · Not reportedDisposal · 25 Jul 2026 · $28.0KDisposal · 11 May 2026 · $135.6KAcquisition · 24 Apr 2026 · Not reportedAcquisition · 24 Apr 2026 · Not reportedDisposal · 24 Apr 2026 · $120.9KDisposal · 24 Apr 2026 · $22.2KAcquisition · 21 Apr 2026 · Not reportedAcquisition · 21 Apr 2026 · Not reportedAcquisition · 21 Apr 2026 · Not reportedAcquisition · 21 Apr 2026 · Not reported
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
337.00 USD
One-week move
+8.9%
Four-week move
+12.9%
Fair-value gap
+11.9%
Trend signal
Active
Relative strength
3.6

Directional balance

Controlled event mix

0.0%acquisition
Acquisition events
0
Disposal events
4
Net value
-$306.6K

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
001 Jun
008 Jun
015 Jun
022 Jun
029 Jun
006 Jul
013 Jul
320 Jul
027 Jul
003 Aug
010 Aug

Named participants

Insider conviction by person

EDWARDS, JEFFREY LDirector500 events
HINCKLEY, GREG KDirector500 events
PEI, MELINDA LITHERLANDDirector500 events
PINKSTON, ARNOLD ADirector500 events
ENLOE, COURTNEY CEVP, General Counsel & Sec281 events
LAKKARAJU, ROOP KALYANEVP, Chief Financial Officer281 events
ENGELHARDT, EVA ANETTEEVP, President, CDG252 events

Evidence quality

Security and transaction context

Common equity11
Equity compensation11
Options and derivatives0
Other securities0

Role architecture

Who is participating

Director12
Other executive7
Finance leadership3

Transaction evidence

Auditable BIO-B filing ledger

Showing 1 to 22 of 22.

ENGELHARDT, EVA ANETTEEVP, President, CDG
AcquisitionCommon equity
246 sharesBio-Rad A Common Stock
Not reportedContext evidence
ENGELHARDT, EVA ANETTEEVP, President, CDG
DisposalEquity compensation
246 sharesRestricted Stock Units
Not reportedContext evidence
ENGELHARDT, EVA ANETTEEVP, President, CDG
DisposalCommon equity
89 sharesBio-Rad A Common Stock
$28.0KDirectional evidence
ENGELHARDT, EVA ANETTEEVP, President, CDG
DisposalCommon equity
550 sharesBio-Rad A Common Stock
$135.6KDirectional evidence
ENLOE, COURTNEY CEVP, General Counsel & Sec
AcquisitionCommon equity
186 sharesBio-Rad A Common Stock
Not reportedContext evidence
ENLOE, COURTNEY CEVP, General Counsel & Sec
DisposalEquity compensation
186 sharesRestricted Stock Units
Not reportedContext evidence
LAKKARAJU, ROOP KALYANEVP, Chief Financial Officer
DisposalEquity compensation
1078 sharesRestricted Stock Units
Not reportedContext evidence
LAKKARAJU, ROOP KALYANEVP, Chief Financial Officer
AcquisitionCommon equity
1078 sharesBio-Rad A Common Stock
Not reportedContext evidence
LAKKARAJU, ROOP KALYANEVP, Chief Financial Officer
DisposalCommon equity
420 sharesBio-Rad A Common Stock
$120.9KDirectional evidence
ENLOE, COURTNEY CEVP, General Counsel & Sec
DisposalCommon equity
77 sharesBio-Rad A Common Stock
$22.2KDirectional evidence
EDWARDS, JEFFREY LDirector
DisposalEquity compensation
407 sharesRestricted Stock Units
Not reportedContext evidence
EDWARDS, JEFFREY LDirector
AcquisitionEquity compensation
369 sharesRestricted Stock Units
Not reportedContext evidence
EDWARDS, JEFFREY LDirector
AcquisitionCommon equity
407 sharesBio-Rad A Common Stock
Not reportedContext evidence
HINCKLEY, GREG KDirector
AcquisitionEquity compensation
369 sharesRestricted Stock Units
Not reportedContext evidence
HINCKLEY, GREG KDirector
AcquisitionCommon equity
407 sharesBio-Rad A Common Stock
Not reportedContext evidence
HINCKLEY, GREG KDirector
DisposalEquity compensation
407 sharesRestricted Stock Units
Not reportedContext evidence
PEI, MELINDA LITHERLANDDirector
DisposalEquity compensation
407 sharesRestricted Stock Units
Not reportedContext evidence
PEI, MELINDA LITHERLANDDirector
AcquisitionEquity compensation
369 sharesRestricted Stock Units
Not reportedContext evidence
PEI, MELINDA LITHERLANDDirector
AcquisitionCommon equity
407 sharesBio-Rad A Common Stock
Not reportedContext evidence
PINKSTON, ARNOLD ADirector
AcquisitionCommon equity
407 sharesBio-Rad A Common Stock
Not reportedContext evidence
PINKSTON, ARNOLD ADirector
DisposalEquity compensation
407 sharesRestricted Stock Units
Not reportedContext evidence
PINKSTON, ARNOLD ADirector
AcquisitionEquity compensation
369 sharesRestricted Stock Units
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context